Onaivi ES (2009) Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology,
neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 88:335– 369
Onaivi ES (2011) Commentary: functional neuronal CB2 cannabinoid receptors in the CNS. Curr
Neuropharmacol 9:205– 208
Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR (2002)
Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 66:307– 344
Onaivi ES, Sugiura T, Di Marzo V (eds) (2006) Endocannabinoids: the brain and body’s
marijuana and beyond. CRC Press, Taylor and Francis Group, Boca Raton
Onaivi ES, Carpio O, Ishiguro H, Schanz N, Uhl GR, Benno R (2008a) Behavioral effects of CB2
cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y
Acad Sci 1139:426– 433
Onaivi ES, Ishiguro H, Gong J-P, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z,
Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Hope B, Lujilde J, Inada T, Iwasaki S,
Macharia D, Teasenfitz L, Arinami T, Uhl GR (2008b) Brain neuronal CB2 cannabinoid
receptors in drug abuse and depression: From mice to human subjects. PLoS ONE 3:e1640
Onaivi ES, Ishiguro H, Gu S, Liu Q-R (2012) CNS effects of CB2 cannabinoid receptors: beyond
neuro-immuno-cannabinoid activity. J Psychopharmacol 26:92– 103
Onaivi ES, Ishiguro H, Sgro S, Leonard CM (2013) Cannabinoid receptor gene variations in drug
addiction and neuropsychiatric disorders. J Drug Alcohol Res 2, ID235714
Onaivi ES, Ishiguro H, Liu QR (2015) In: Fattore L (ed) Cannabinoids in neurologic and mental
disease, Elsevier Inc. Future perspectives: Cannabinoid CB2 receptor ligands and their
therapeutic potential in mental diseases. Chapter 18: 425– 444
Paldy E, Bereczki E, Santha M, Wenger T, Borsodi A, Zimmer A, Benhyhe S (2008) CB2
cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and
activation in mouse brainstem: role of CB2 receptor in pain. Neurochem Int 53:309– 316
Paldyova E, Bereczki E, Santha M, Wenger T, Borsodi A, Benyhe S (2008) Oladin ether, a
putative endocannabinoid, inhibits mu-opoid receptor activation via CB2 cannabinoid
receptors. Neurochem Int 52:321– 328
Palomo T, Kostrzewa RM, Beninger RJ, Archer T (2007) Genetic variation and shared biological
susceptibility underlying comorbidity in neuropsychiatry. Neurotox Res 12:29– 42
Pazos MR, Nunez E, Benito C, Tolon RM, Romero J (2004) Role of the endocannabinoid system
in Alzheimer’s disease: new perspectives. Life Sci 75:1907– 1915
Reinhard W, Stark K, Neureuther K, Sedlacek K, Fischer M, Baessler A, Weber S, Kaess B,
Wiedmann S, Erdmann J, Lieb W, Jeron A, Riegger G, Hengstenberg C (2008) Common
polymorphisms in the cannabinoid CB2 gene (CNR2) are not associated with myocardial
infarction and cardiovascular risk factors. Int J Mole Med 22:165– 174
Rogers N (2015) Cannabinoid receptor with an“identity crisis”gets a second look. Nat Med
21:967
Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O, Le Fur G,
Caput D, Ferrara P (1996) Molecular cloning, expression and function of the murine CB2
peripheral cannabinoid receptor. Biochim Biophys Act 1307:132– 136
Sipe JC, Arbour N, Gerber A, Beutler E (2005) Reduced endocannabinoid immune modulation by
a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune
disorders. J Leukoc Biol 78:231– 238
Steiner MA, Marsicano G, Wotjak CA, Lutz B (2008) Conditional cannabinoid receptor type 1
mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress
responses. Psychoneuroendocrinology 33:1165– 1170
Stempel AV, Stumpf A, Zhang H-Y, Ozdogan T, Pannasch U, Theis A-K, Otte D-M, Wojtalla A,
Racz I, Ponomarenko A, Xi Z-X, Zimmer A, Schmitz D (2016) Cannabinoid type 2 receptors
mediate a cell type-specific plasticity in the hippocampus. Neuron 90:1– 15
Suarez J, Bermudez-Silva FJ, Mackie K, Ledent C, Zimmer A, Cravatt BF, de Fonseca FR (2008)
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum
and functionally related nuclei. J Comp Neurol 509:400– 421
246 E.S. Onaivi et al.